Advertisement

 

 

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn’s disease – should one consider disease location?

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn’s disease – should one consider disease location?
Author Information (click to view)

Srinivas NR,


Srinivas NR, (click to view)

Srinivas NR,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Alimentary pharmacology & therapeutics 44(7) 771-2 doi 10.1111/apt.13743
Abstract

Submit a Comment

Your email address will not be published. Required fields are marked *

5 × three =

[ HIDE/SHOW ]